NASPCC Webinar Series Presents: “Theranostics in Prostate Cancer"

Written By PCRI
f50d47adc2f4d05f5979bc266d23eb2b.jpeg

NASPCC Webinar Series Presents:

“Theranostics in Prostate Cancer*”

With Dr. Michael Morris, Section Head of Prostate Cancer, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center in New York

The 1-hour Webinar will take place on Monday, January 11, 2021 from 7:00 pm – 8:00 pm Eastern.

To register for this event, please click here or visit the NASPCC website at www.NASPCC.org

f50d47adc2f4d05f5979bc266d28e65d.jpeg

Dr. Morris is a prostate cancer specialist, clinical investigator, and the Section Head of Prostate Cancer of the Genitourinary Oncology Service at Memorial Sloan-Kettering Cancer Center. He earned his medical degree from the Mount Sinai School of Medicine in New York, and performed his internship and residency in Internal Medicine at Columbia Presbyterian Medical Center. He then completed his medical oncology fellowship at Memorial Sloan-Kettering Cancer Center, where he was the Chief Fellow as well.

Dr. Morris has led numerous clinical trials, but he has a particular research focus on targeted therapy for prostate cancer, especially those that bridge the fields of Medical Oncology and Nuclear Medicine. In the field of therapeutics, he has focused on radio immunotherapy and other radio-conjugates, bone directed therapy, and other targeted therapies. In the field of diagnostics, he has a keen research interest in developing novel imaging technologies for metastatic prostate cancer and in developing novel imaging biomarkers. He has been a co-developer of the Prostate Cancer Working Group 2 and 3 Consensus Criteria, and novel prostate-specific imaging technologies such as FDHT PET and PSMA-directed PET imaging.

In addition, he is the Medical Director of the Department of Prostate Cancer Clinical Consortium and chairs the GU Committee of the Alliance for Oncology Trials in Oncology (formerly CALGB).

* Theranostics describes the combination of using one radioactive drug to diagnose and a second radioactive drug to deliver therapy to treat the main tumor and any metastases.

PCRI
Previous

Press Release: Lantheus Holdings Submits New Drug Application to the U.S. FDA for PyLTM (18F-DCFPyL), a PSMA-Targeted Prostate Cancer Imaging Agent
Next

NASPCC Webinar Series Presents: “Incontinence and Sexual Side Effects of Prostate Cancer Treatment”